Journal article
Docosahexaenoic acid and bronchopulmonary dysplasia in preterm infants
CT Collins, M Makrides, AJ McPhee, TR Sullivan, PG Davis, M Thio, K Simmer, VS Rajadurai, J Travadi, MJ Berry, HG Liley, GF Opie, K Tan, K Lui, SA Morris, J Stack, MJ Stark, MC Chua, PA Jayagobi, J Holberton Show all
New England Journal of Medicine | Published : 2017
Abstract
Background: Studies in animals and in humans have suggested that docosahexaenoic acid (DHA), an n-3 long-chain polyunsaturated fatty acid, might reduce the risk of bronchopulmonary dysplasia, but appropriately designed trials are lacking. Methods: We randomly assigned 1273 infants born before 29 weeks of gestation (stratified according to sex, gestational age [<27 weeks or 27 to <29 weeks], and center) within 3 days after their first enteral feeding to receive either an enteral emulsion providing DHA at a dose of 60 mg per kilogram of body weight per day or a control (soy) emulsion without DHA until 36 weeks of postmenstrual age. The primary outcome was bronchopulmonary dysplasia, defined on..
View full abstractRelated Projects (1)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Supported by a grant (1022112) from the NHMRC, by the M.S. McLeod Research Fund, Women's and Children's Hospital Research Foundation (M.S. McLeod Research Fellowship to Dr. Collins), and by NHMRC Fellowships (Principal Research Fellowship 1061704 to Dr. Makrides, Practitioner Fellowship 1059111 to Dr. Davis, Early Career Research Fellowship 1111134 to Dr. Thio, and Senior Principal Research Fellowship 1046207 to Dr. Gibson).